# The Column Group: portfolio, investments and team > The Column Group is a vc firm based in United States. 46 investments on record, 1 in the last 12 months, latest Oct 2026. Source: https://millionrounds.com/fund/the-column-group (Millionrounds; every figure on the page links to its filing or article) United States · [Investor](https://millionrounds.com/investors) # The Column Group Last cheque observed Oct 2026; 46 cheques on record. Email Deploying now New fund $100M, Dec 2025 VC firm Seed Series A Series B Life Sciences Follow The Column Group and see its new cheques in your feed. [Start following](https://millionrounds.com/login?join=1&why=follow&next=%2Ffund%2Fthe-column-group) Deploying now **100%** of best year **1** **cheques in 12 months**, 46 on record Since the last cheque **29** days **00** hrs **00** min **00** sec Median round **$57M** Cheque size, as they say **$100K – $5.0M** Rounds led **2 of 46** Sole investor **4 rounds** Exits **3 from the portfolio** Mostly in **United States, 100%** Pitch The Column Group ## The Column Group highlights - 01 1 cheques in the last 12 months - 02 Mostly Series A and Series B: 73% of its rounds - 03 Sole investor in 4 rounds, median $24M - 04 3 exits from the portfolio ## What they do > The Column Group (TCG) is a venture ecosystem dedicated to fueling scientific innovation in the life sciences industry. From their own website - **Type:** VC firm (from a list, unverified) - **Cheque size:** $100K – $5.0M as they say - **Stages:** Seed Series A Series B Growth Pre-IPO - **Sectors:** Life Sciences - **Based in:** San Francisco, United States - **Cold pitches:** Not stated ## The record Every round we can evidence, newest first **46 appearances** - **2026** 1 round - **Oct** **[TriGemX Bio](https://millionrounds.com/company/trigemx-bio)** US · AlleyWatch **$94M** *Led* - **2019** 4 rounds - **Nov** **[A2 Biotherapeutics](https://millionrounds.com/company/a2-biotherapeutics)** Series A · US · FinSMEs **$57M** With 3 others - **Oct** **[Plexium](https://millionrounds.com/company/plexium)** Series A · US · Plexium **$28M** *Led* - **Oct** **[Tenaya Therapeutics](https://millionrounds.com/company/tenaya-therapeutics)** Series B · US · FinSMEs **$92M** With 2 others - **Jul** **[Revolution Medicines](https://millionrounds.com/company/revolution-medicines)** Series C · US · FinSMEs **$100M** With 9 others - **2018** 7 rounds - **Dec** **[Kallyope](https://millionrounds.com/company/kallyope)** Series B · US · FinSMEs **$21M** With 6 others - **May** **[Accent](https://millionrounds.com/company/accent)** Series A · US · Xconomy **$40M** With 2 others - **May** **[Escient](https://millionrounds.com/company/escient)** Series A · US · FinSMEs **$40M** With 2 others - **Apr** **[Constellation](https://millionrounds.com/company/constellation)** US · FinSMEs **$100M** With 12 others - **Feb** **[Kallyope](https://millionrounds.com/company/kallyope)** Series B · US · FinSMEs **$66M** With 6 others - **Feb** **[ORIC](https://millionrounds.com/company/oric)** Series C · US · FinSMEs **$50M** With 8 others - **Jan** **[Ribon Therapeutics](https://millionrounds.com/company/ribon-therapeutics)** Series B · US · Marketwatch **$65M** With 7 others - **2017** 4 rounds - **Dec** **[FLX Bio](https://millionrounds.com/company/flx-bio)** Series C · US · Vcnewsdaily **$60M** With 4 others - **Sept** **[Gritstone](https://millionrounds.com/company/gritstone)** Series B · US · FinSMEs **$93M** With 6 others - **Jul** **[eFFECTOR Therapeutics](https://millionrounds.com/company/effector-therapeutics)** Series C · US · FinSMEs **$39M** With 10 others - **Feb** **[Surrozen](https://millionrounds.com/company/surrozen)** Series A · US · FinSMEs **$33M** Sole investor - **2016** 1 round - **Dec** **[Revolution Medicines](https://millionrounds.com/company/revolution-medicines)** Series A · US · FinSMEs **$25M** Sole investor - **2015** 3 rounds - **Dec** **[ORIC Pharmaceuticals](https://millionrounds.com/company/oric-pharmaceuticals)** Series B · US **$53M** With 5 others - **Dec** **[Neuron Therapeutics](https://millionrounds.com/company/neuron-therapeutics)** Series A · US **$24M** Sole investor - **Oct** **[Gritstone oncology](https://millionrounds.com/company/gritstone-oncology)** Series A · US **$102M** With 6 others - **2014** 3 rounds - **Dec** **[Flexus Biosciences](https://millionrounds.com/company/flexus-biosciences)** Series B · US **$38M** With 2 others - **May** **[Nurix](https://millionrounds.com/company/nurix)** Series B · US **$25M** With 1 other - **Jan** **[Igenica](https://millionrounds.com/company/igenica)** Series C · US **$14M** With 3 others - **2013** 1 round - **Oct** **[Immune Design](https://millionrounds.com/company/immune-design)** Series C · US · finsmes.com **$49M** With 6 others - **2012** 5 rounds - **Oct** **[Aragon Pharmaceuticals](https://millionrounds.com/company/aragon-pharmaceuticals)** Series D · US · prnewswire.com **$50M** With 3 others - **Oct** **[Igenica](https://millionrounds.com/company/igenica)** Growth · US **$10M** With 3 others - **Jul** **[Carmot Therapeutics](https://millionrounds.com/company/carmot-therapeutics)** Venture · US · sec.gov **$500K** Sole investor - **Jun** **[Igenica](https://millionrounds.com/company/igenica)** Series C · US · finsmes.com **$33M** With 3 others - **May** **[Nurix](https://millionrounds.com/company/nurix)** Seed · US · xconomy.com **$3.1M** With 1 other - **2011** 3 rounds - **Jul** **[Peloton Therapeutics](https://millionrounds.com/company/peloton-therapeutics)** Series A · US · finsmes.com **$18M** With 1 other - **Jun** **[Cyterix Pharmaceuticals](https://millionrounds.com/company/cyterix-pharmaceuticals)** Series A · US · finsmes.com **$9.2M** With 1 other - **Jun** **[Constellation Pharmaceuticals](https://millionrounds.com/company/constellation-pharmaceuticals)** Series B · US · finsmes.com **$15M** With 4 others - **2010** 4 rounds - **Jul** **[Immune Design](https://millionrounds.com/company/immune-design)** Series B · US · xconomy.com **$32M** With 4 others - **Jun** **[Igenica](https://millionrounds.com/company/igenica)** Series B · US · onbiovc.com **$24M** With 2 others - **Jun** **[Constellation Pharmaceuticals](https://millionrounds.com/company/constellation-pharmaceuticals)** Series B · US · onbiovc.com **$22M** With 4 others - **Apr** **[Aragon Pharmaceuticals](https://millionrounds.com/company/aragon-pharmaceuticals)** Series B · US · fiercebiotech.com **$22M** With 2 others - **2009** 7 rounds - **Dec** **[PTC Therapeutics](https://millionrounds.com/company/ptc-therapeutics)** Series E · US · finsmes.com **$50M** With 4 others - **Dec** **[PTC Therapeutics](https://millionrounds.com/company/ptc-therapeutics)** Growth · US **$50M** With 4 others - **Dec** **[NGM Biopharmaceuticals](https://millionrounds.com/company/ngm-biopharmaceuticals)** Series A · US · sec.gov **$27M** With 2 others - **Aug** **[Constellation Pharmaceuticals](https://millionrounds.com/company/constellation-pharmaceuticals)** Series A · US **$17M** With 3 others An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor. ## The team Named by the firm itself, on a filing, its Form ADV or its company registration **14 named** DV **David Van Norman Goeddel** Managing Member of the General Partner of the General Partner i Filing they signed DV **David V. Goeddel, Ph.D.** Managing Partner of The Column Group II GP, LP, the general partner i Filing they signed DV **David V Goeddel Ph D** Executive Officer i Filing they signed DV **David V. Goeddel, PHD** Managing Member of the General Partner of the General Partner i Filing they signed HE **Harald Ekman** Managing Partner of The Column Group II GP, LP, the general partner i Filing they signed JP **James Philip Evangelista** Chief Financial Officer i Form ADV LV **Laurence V. Lasky, Ph.D.** Executive Officer i Filing they signed MP **Magnus Persson, M.D., Ph.D.** Managing Partner of The Column Group II GP, LP, the general partner i Filing they signed PH **Peter Haqvin Erland Svennilson** Managing Partner of The Column Group II GP, LP, the general partner i Filing they signed RK **Richard Klausner, M.D.** Managing Partner of The Column Group II GP, LP, the general partner i Filing they signed TV **Tim V Kutzkey** Managing Member of the General Partner of the General Partner i Filing they signed TV **Tim V. Kutzkey, PHD** Managing Member of the General Partner of the General Partner i Filing they signed TV **Tim V. Kutzkey, Ph.D.** Executive Officer i Filing they signed TW **Timothy William Kutzkey** Managing Partner i Form ADV We also hold **23** people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them. ## What the register says From the firm's own filings with the SEC, which it must file accurately by law **$3.3B** gross assets of its funds Oct 2026 **Exempt** reporting adviser venture or small private funds - **Legal name:** The Column Group Management LP - **SEC number:** CRD 161912 ## What they claim to have backed From their own portfolio page (on their website) **10** of 29 we have independently watched raise [Thumbnail for A2 Biotherapeutics](https://millionrounds.com/company/a2-biotherapeutics)[Thumbnail for Arcus Biosciences](https://millionrounds.com/company/arcus-biosciences)[Thumbnail for Circle Pharma](https://millionrounds.com/company/circle-pharma)[Thumbnail for Kallyope](https://millionrounds.com/company/kallyope)[Thumbnail for Oric Pharmaceuticals](https://millionrounds.com/company/oric-pharmaceuticals)[Thumbnail for Peloton Therapeutics](https://millionrounds.com/company/peloton-therapeutics)[Thumbnail for Plexium](https://millionrounds.com/company/plexium)[Thumbnail for Revolution Medicines](https://millionrounds.com/company/revolution-medicines)[Thumbnail for Surrozen](https://millionrounds.com/company/surrozen)[Thumbnail for Tenaya Therapeutics](https://millionrounds.com/company/tenaya-therapeutics) Novartis Thumbnail for Aragon Pharmaceuticals Thumbnail for Atavistik Bio Thumbnail for Carmot Therapeutics Thumbnail for Escient Pharmaceuticals Thumbnail for Gritstone Bio Thumbnail for Hexagon Bio Thumbnail for Immune Design Thumbnail for Judo Bio Thumbnail for Lyterian Therapeutics Thumbnail for Neurona Therapeutics Thumbnail for Ngm Bio Thumbnail for Nura Bio Thumbnail for Rapt Therapeutics Thumbnail for Seragon Pharmaceuticals Thumbnail for SyntheX Thumbnail for Synthekine Thumbnail for Tortugas Neuroscience Thumbnail for Tr1x Bio Weaker than a round we watched, stronger than a list somebody sold us. A firm is far less willing to put a company on its own site that it never funded. ## Exits from the portfolio Companies it backed that were later bought or listed **3 in all** **[Flexus Biosciences](https://millionrounds.com/company/flexus-biosciences)** Bought by [Bristol-Myers Squibb](https://millionrounds.com/fund/bristol-myers-squibb) **$1.3B** Feb 2015 **[PTC Therapeutics](https://millionrounds.com/company/ptc-therapeutics)** Listed **$125M** Jun 2013 **[Aragon Pharmaceuticals](https://millionrounds.com/company/aragon-pharmaceuticals)** Bought by [Johnson & Johnson](https://millionrounds.com/fund/johnson-and-johnson) **$1.0B** Jun 2013 An exit counts when it came after the firm's first round in the company. From historical deal records. New fund on file **$100M** raised in Dec 2025 From its SEC filing, not a journalist: a firm that has just raised has money to deploy. ## The cheque Seed Series A Series B Median round joined **$57M** the round, not its cheque Alone, median **$24M** Led 2 of 46 rounds **4%** - **Said size:** $100K – $5.0M - **Sole investor:** 4 rounds - **Last cheque:** Oct 2026 - **Exits:** 3 from the portfolio Rounds by stage said on their site - Series A said *15* - Series B said *15* - Series C *7* - Venture *2* - Growth said *2* - Seed said *-* - Pre-IPO said *-* Cheques by month Led Joined Nov 2023 Oct 2026 Often in the room with - [Third Rock Ventures](https://millionrounds.com/fund/third-rock-ventures) 11 - [OrbiMed](https://millionrounds.com/fund/orbimed) 10 - [Versant Ventures](https://millionrounds.com/fund/versant-ventures) 6 - [5AM Ventures](https://millionrounds.com/fund/5am-ventures) 5 - [Venrock](https://millionrounds.com/fund/venrock) 5 - [Alta Partners](https://millionrounds.com/fund/alta-partners) 4 **Pitching The Column Group?** Put them on your fundraising board with this record on the card, and follow them to hear when they write a new cheque. Add to your CRM *→* ## Who they invest alongside The investors most often in the same rounds as The Column Group. A count of rooms they were both in, not a relationship either has claimed. [**Third Rock Ventures** VC firm **11** rounds together](https://millionrounds.com/fund/third-rock-ventures)[**OrbiMed** Private equity **10** rounds together](https://millionrounds.com/fund/orbimed)[**Versant Ventures** VC firm **6** rounds together](https://millionrounds.com/fund/versant-ventures)[**5AM Ventures** VC firm **5** rounds together](https://millionrounds.com/fund/5am-ventures)[**Venrock** VC firm **5** rounds together](https://millionrounds.com/fund/venrock)[**Alta Partners** VC firm **4** rounds together](https://millionrounds.com/fund/alta-partners)[**Casdin Capital** VC firm **4** rounds together](https://millionrounds.com/fund/casdin-capital)[**Osage University Partners** VC firm **4** rounds together](https://millionrounds.com/fund/osage-university-partners)[**SR One** Corporate VC **4** rounds together](https://millionrounds.com/fund/sr-one)[**Alexandria Real Estate Equities** VC firm **3** rounds together](https://millionrounds.com/fund/alexandria)[**Celgene** Growth equity **3** rounds together](https://millionrounds.com/fund/celgene)[**Deerfield** VC firm **3** rounds together](https://millionrounds.com/fund/deerfield) ## Recently backed The latest companies The Column Group put money into. [**A2 Biotherapeutics** $57M · Nov 2019](https://millionrounds.com/company/a2-biotherapeutics)[**Plexium** $28M · Oct 2019](https://millionrounds.com/company/plexium)[**Tenaya Therapeutics** $92M · Oct 2019](https://millionrounds.com/company/tenaya-therapeutics)[**Revolution Medicines** $100M · Jul 2019](https://millionrounds.com/company/revolution-medicines)[**Kallyope** $21M · Dec 2018](https://millionrounds.com/company/kallyope)[**Escient** $40M · May 2018](https://millionrounds.com/company/escient) ## Quick answers about The Column Group ### What does The Column Group invest in? The Column Group invests most often at Series A and Series B (73% of the rounds on record), in sectors such as Life Sciences. ### How active is The Column Group? 46 investments on record, 1 of them in the last 12 months, and it led 2. The most recent was in Oct 2026. ### What has The Column Group invested in recently? Its most recent investments on record: TriGemX Bio (Undisclosed round, Oct 2026), A2 Biotherapeutics (Series A, Nov 2019) and Plexium (Series A, Oct 2019). ### How big are The Column Group's cheques? The median round it joins is $57M. It says it writes cheques of $100K to $5.0M. ### Does The Column Group lead rounds? Sometimes: it led 2 of its 46 investments on record (4%). ### Where does The Column Group invest? Most of the companies it backs are in the United States (100%). ### Is The Column Group investing now? Yes: it is actively investing, with 1 investments in the last 12 months. ### Who does The Column Group invest alongside? Most often Third Rock Ventures (11 rounds together), OrbiMed (10 rounds together) and Versant Ventures (6 rounds together). ## Raising now? Find the investors who back rounds like yours, and keep every conversation on one fundraising board. Find similar investorsOpen your CRM Built from the rounds we watched, its filings and its own website, refreshed every night. [How we count](https://millionrounds.com/methodology) · [Report a correction](https://millionrounds.com/corrections?slug=the-column-group) · [Is this your firm? Claim it](https://millionrounds.com/claim?org=the-column-group)